Hyung C. Suh

931 total citations
44 papers, 636 citations indexed

About

Hyung C. Suh is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Hyung C. Suh has authored 44 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 20 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Hyung C. Suh's work include Acute Myeloid Leukemia Research (16 papers), CAR-T cell therapy research (15 papers) and Hematopoietic Stem Cell Transplantation (10 papers). Hyung C. Suh is often cited by papers focused on Acute Myeloid Leukemia Research (16 papers), CAR-T cell therapy research (15 papers) and Hematopoietic Stem Cell Transplantation (10 papers). Hyung C. Suh collaborates with scholars based in United States, Canada and South Korea. Hyung C. Suh's co-authors include Jonathan R. Keller, Kimberly D. Klarmann, John Gooya, Peter F. Johnson, Mary Beth Hilton, Cyril Berthet, Philipp Kaldis, Hiroaki Kiyokawa, Ming Ji and Alan D. Friedman and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hyung C. Suh

38 papers receiving 625 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hyung C. Suh United States	13	383	186	178	153	78	44	636
Shannon M. Buckley United States	13	598 1.6×	141 0.8×	165 0.9×	70 0.5×	73 0.9×	19	770
Bryan Zimdahl United States	8	359 0.9×	130 0.7×	220 1.2×	126 0.8×	48 0.6×	10	600
Susan Sutton United States	9	344 0.9×	164 0.9×	211 1.2×	303 2.0×	62 0.8×	10	742
Mikkel Bruhn Schuster Denmark	15	641 1.7×	379 2.0×	116 0.7×	180 1.2×	56 0.7×	24	895
Riccardo Panero Italy	7	403 1.1×	324 1.7×	111 0.6×	236 1.5×	33 0.4×	8	810
Huen Suk Kim United States	9	382 1.0×	161 0.9×	98 0.6×	100 0.7×	59 0.8×	11	570
Joby L. McKenzie Canada	7	232 0.6×	281 1.5×	132 0.7×	147 1.0×	98 1.3×	7	517
Andrew Fong Canada	12	361 0.9×	233 1.3×	187 1.1×	208 1.4×	134 1.7×	19	682
Teresa D’Altri Spain	10	450 1.2×	150 0.8×	99 0.6×	155 1.0×	30 0.4×	15	659
Shabnam Kharazi Sweden	12	581 1.5×	391 2.1×	80 0.4×	329 2.2×	65 0.8×	19	937

Countries citing papers authored by Hyung C. Suh

Since Specialization

Citations

This map shows the geographic impact of Hyung C. Suh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyung C. Suh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyung C. Suh more than expected).

Fields of papers citing papers by Hyung C. Suh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyung C. Suh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyung C. Suh. The network helps show where Hyung C. Suh may publish in the future.

Co-authorship network of co-authors of Hyung C. Suh

This figure shows the co-authorship network connecting the top 25 collaborators of Hyung C. Suh. A scholar is included among the top collaborators of Hyung C. Suh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hyung C. Suh. Hyung C. Suh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ahn, Jaeil, Brittany Sinclaire, Christina Cho, et al.. (2025). Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study. SHILAP Revista de lepidopterología. 6(1). 3–3. 1 indexed citations

Kabat, Maciej, Andrew Ip, Hyung C. Suh, et al.. (2025). Peripheral Blood Tumor Associated Cell-Free DNA Testing as a Predictor for Relapse Postallogeneic Stem Cell Transplant for Acute Myelogenous Leukemia. Transplantation and Cellular Therapy. 31(12). 1010–1019.

Rowley, Scott D., Maher Albitar, Alaa M. Ali, et al.. (2025). cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Cancers. 17(4). 625–625. 1 indexed citations

Malki, Monzr M. Al, Alla Keyzner, Yibin Chen, et al.. (2025). TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation and Cellular Therapy. 31(2). S59–S60.

Malki, Monzr M. Al, Alla Keyzner, Hyung C. Suh, et al.. (2024). A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.. Journal of Clinical Oncology. 42(16_suppl). TPS2678–TPS2678. 1 indexed citations

DiPersio, John F., Guenther Koehne, Nirali N. Shah, et al.. (2024). A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML). Blood. 144(Supplement 1). 2873–2873.

Rowley, Scott D., Albert Lee, Hong Zhang, et al.. (2024). Using Targeted Transcriptome and Machine Learning of Pre- and Post-Transplant Bone Marrow Samples to Predict Acute Graft-versus-Host Disease and Overall Survival after Allogeneic Stem Cell Transplantation. Cancers. 16(7). 1357–1357. 5 indexed citations

Biran, Noa, Hyung C. Suh, Christina Cho, et al.. (2023). Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma. Blood. 142(Supplement 1). 6903–6903. 1 indexed citations

Koehne, Guenther, Benjamin Tomlinson, Hyung C. Suh, et al.. (2023). P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS. HemaSphere. 7(S3). e24418bc–e24418bc. 3 indexed citations

10.

Devlin, Sean M., Beatriz Wills, Amethyst Saldia, et al.. (2023). Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy. Blood. 142(Supplement 1). 3510–3510. 1 indexed citations

11.

Gelman, Simon, et al.. (2023). Graft-Versus-Host Disease (GvHD) Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation (haplo-PBSCT) Using Abatacept in Combination with Post-Transplant Cyclophosphamide (PTCy). Blood. 142(Supplement 1). 6996–6996.

12.

Albitar, Maher, Hong Zhang, Andrew L. Pecora, et al.. (2021). Reliability of Liquid Biopsy and Next Generation Sequencing in Monitoring Residual Disease Post-Hematopoietic Stem Cell Transplant. Blood. 138(Supplement 1). 1828–1828. 1 indexed citations

13.

Cortés, María de las Aguas Robustillo, et al.. (2021). Assessment of Serology after Sars-Cov-2 Vaccine in Allogeneic HCT Recipients. Blood. 138(Supplement 1). 2900–2900. 1 indexed citations

14.

Himburg, Heather A., Martina Roos, Tiancheng Fang, et al.. (2019). Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling. Journal of Clinical Investigation. 130(1). 315–328. 11 indexed citations

15.

Suh, Hyung C., et al.. (2018). Bioengineered Autologous Dendritic Cells Enhance CAR T Cell Cytotoxicity By Providing Cytokine Stimulation and Intratumoral Dendritic Cells. Blood. 132(Supplement 1). 3693–3693. 13 indexed citations

16.

Suh, Hyung C., et al.. (2017). Effect of dendritic cells (DC) transduced with chimeric antigen receptor (CAR) on CAR T-cell cytotoxicity.. Journal of Clinical Oncology. 35(7_suppl). 144–144. 12 indexed citations

17.

Ji, Ming, Huajie Li, Hyung C. Suh, et al.. (2008). Id2 intrinsically regulates lymphoid and erythroid development via interaction with different target proteins. Blood. 112(4). 1068–1077. 60 indexed citations

18.

Heath, Victoria L., Hyung C. Suh, Matthew J. Holman, et al.. (2004). C/EBPα deficiency results in hyperproliferation of hematopoietic progenitor cells and disrupts macrophage development in vitro and in vivo. Blood. 104(6). 1639–1647. 88 indexed citations

19.

Min, Yoo Hong, Seung‐Tae Lee, Jin Seok Kim, et al.. (2001). Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia. Yonsei Medical Journal. 42(1). 65–65. 1 indexed citations

20.

Lee, Seung‐Tae, et al.. (2001). Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high‐risk myelodysplastic syndrome. American Journal of Hematology. 68(4). 237–245. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact